# ClearPoint Neuro, Inc.

**CLPT**

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001285550

**C**

**middle fifth of 305 graded peers in healthcare**

rank 154 of 305; percentile 50.3; sampling error 2.8 points; lower is stronger

A B C D E

**C, the tortoise**



## Scoreboard

| | |
|---|---|
| **Profitability** | D<br>percentile 66.6 |
| **Solvency** | B/C<br>percentile 42.7 |
| **Growth and financing** | B<br>percentile 32.6 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $97.7M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress |
| **Inputs computable** | 8 of 13 |
| **Graded from** | filings received through Mar 17, 2026<br>248 days before the rescan; latest periodic filing 10-Q received Oct 28, 2026 |
| **Last close** | $7.32<br>2026-11-19; market equity $234.6M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 17, 2026*

We are a commercial-stage medical device company, incorporated in 1998 as a Delaware corporation, that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. From our inception in 1998, we have deployed significant resources to fund our efforts to develop the foundational capabilities for enabling magnetic resonance imaging ("MRI") guided interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies we develop.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 66.6** | | | | | | |
| Gross profitability | 23.2% | 32.8% | | 58.8 | 346 | 2025-12-31 |
| Return on invested capital | not computable | 9.6% | | | | |
| *prior invested-capital observation is 731 days earlier* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (2.4%) | (6.7%) | 75.2 | 756 | 2025-12-31 |
| Gross margin stability, five years | 4.0 pts | 2.8 pts | 65.7 | 237 | 2025-12-31 |
| **Solvency, sleeve percentile 42.7** | | | | | |
| Altman Z double-prime | (4.93) | 0.31 | 53.4 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *EBITDA must exceed $100,000* | | | | | |
| Interest coverage | not computable | (3.61x) | | | |
| *interest expense must exceed $100,000* | | | | | |
| Current ratio | 5.91x | 2.68x | 32.1 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 32.6** | | | | | |
| Revenue growth, three-year compound | 21.6% | 9.6% | 29.6 | 400 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 33.9% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | 20.8% | 3.2% | 20.2 | 663 | 2025-12-31 |
| Net share issuance, one year | 7.4% | 1.6% | 48.1 | 625 | 2026-03-06 |

## Among 305 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 149 | Repligen Corp. (RGEN) | 48.7 | C | late filer, fortress balance sheet |
| 150 | Zimmer Biomet Holdings, Inc. (ZBH) | 49.0 | C | |
| 151 | Enovis Corp. (ENOV) | 49.3 | C | |
| 152 | Anika Therapeutics, Inc. (ANIK) | 49.7 | C | fortress balance sheet |
| 153 | Kymera Therapeutics, Inc. (KYMR) | 50.0 | C | dilution |
| 154 | ClearPoint Neuro, Inc. (CLPT) | 50.3 | C | |
| 155 | Align Technology Inc. (ALGN) | 50.7 | C | |
| 156 | Amneal Pharmaceuticals, Inc. (AMRX) | 51.0 | C | |
| 157 | Biodesix Inc. (BDSX) | 51.3 | C | dilution |
| 158 | Pacira BioSciences, Inc. (PCRX) | 51.6 | C | |
| 159 | Macrogenics Inc. (MGNX) | 52.0 | C | |

## What the price implies

*at the 2026-11-19 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (47.4%) | (1.7%) | 16 |
| Distance from 52-week high | (62.4%) | (31.7%) | 22 |
| EBIT to enterprise value | (10.1%) | 0.5% | 29 |
| Free cash flow yield | (10.4%) | 0.6% | 27 |
| Book value to price | 0.12 | 0.29 | 26 |
| Sales to price | 0.16 | 0.37 | 27 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Composite equity issuance, five years | 43.9% | 13.5% | 72 |
| Relative strength against the sector, log excess return | (0.81) | (0.19) | 16 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $46.2M |
| Operating cash flow, four quarters | -$47.2M |
| Months of runway | 11.8 |
| Days since last periodic filing | 23 (10-Q received Oct 28, 2026) |
| Median daily dollar volume, 63 sessions | $7.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $22.7M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 2 | assets | us-gaap:Assets | $97.7M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | -$24.2M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$25.5M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $55,000 | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 6 | total debt | us-gaap:LongTermDebt | $49.1M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 7 | book equity | us-gaap:StockholdersEquity | $28.0M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $45.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 9 | total debt | us-gaap:LongTermDebt | $9.9M | 2023-12-31 | 2024-03-12 | 10-K | 24-000031 |
| 10 | book equity | us-gaap:StockholdersEquity | $21.2M | 2023-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $23.1M | 2023-12-31 | 2025-02-26 | 10-K | 25-027934 |
| 12 | net income | us-gaap:NetIncomeLoss | -$25.5M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$23.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 14 | assets | us-gaap:Assets | $39.2M | 2024-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $37.0M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 16 | gross profit | us-gaap:GrossProfit | $19.1M | 2024-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $31.4M | 2024-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 18 | gross profit | us-gaap:GrossProfit | $13.6M | 2023-12-31 | 2025-02-26 | 10-K | 25-027934 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $24.0M | 2023-12-31 | 2025-02-26 | 10-K | 25-027934 |
| 20 | gross profit | us-gaap:GrossProfit | $13.5M | 2022-12-31 | 2024-03-12 | 10-K | 24-000031 |
| 21 | revenue | us-gaap:Revenues | $20.6M | 2022-12-31 | 2024-03-12 | 10-K | 24-000031 |
| 22 | gross profit | us-gaap:GrossProfit | $11.1M | 2021-12-31 | 2023-03-01 | 10-K | 23-000020 |
| 23 | revenue | us-gaap:Revenues | $16.3M | 2021-12-31 | 2023-03-01 | 10-K | 23-000020 |
| 24 | current assets | us-gaap:AssetsCurrent | $63.6M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $10.8M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 26 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$216.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 27 | liabilities | us-gaap:Liabilities | $69.7M | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $814,000 | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 29 | operating income | us-gaap:OperatingIncomeLoss | -$16.3M | 2022-12-31 | 2024-03-12 | 10-K | 24-000031 |
| 30 | interest expense | us-gaap:InterestExpense | $81,000 | 2022-12-31 | 2023-03-01 | 10-K | 23-000020 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $522,000 | 2025-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.9M | 2024-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 33 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $275,000 | 2024-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 34 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$13.7M | 2023-12-31 | 2025-02-26 | 10-K | 25-027934 |
| 35 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $717,000 | 2023-12-31 | 2025-02-26 | 10-K | 25-027934 |
| 36 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$16.2M | 2022-12-31 | 2024-03-12 | 10-K | 24-000031 |
| 37 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $253,000 | 2022-12-31 | 2024-03-12 | 10-K | 24-000031 |
| 38 | current assets | us-gaap:AssetsCurrent | $33.4M | 2024-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 39 | current liabilities | us-gaap:LiabilitiesCurrent | $10.4M | 2024-12-31 | 2026-03-17 | 10-K | 26-111231 |
| 40 | assets | us-gaap:Assets | $42.7M | 2023-12-31 | 2025-02-26 | 10-K | 25-027934 |
| 41 | assets | us-gaap:Assets | $55.5M | 2022-12-31 | 2024-03-12 | 10-K | 24-000031 |
| 42 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 29,663,875 | 2026-03-06 | 2026-03-17 | 10-K | 26-111231 |
| 43 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 27,632,332 | 2025-02-18 | 2025-02-26 | 10-K | 25-027934 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.